Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infectious Diseases and Therapy

Open Access 25-04-2024 | Carbapenem Antibiotic | Original Research

Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis

Authors: Tetsuya Matsumoto, Akira Yuasa, Hiroyuki Matsuda, Dilinuer Ainiwaer, Naohiro Yonemoto

Published in: Infectious Diseases and Therapy

Login to get access

Abstract

Introduction

Antimicrobial resistance (AMR) is one of the most serious public health challenges worldwide, including in Japan. However, there is limited evidence assessing the AMR burden in Japan. Thus, this systematic literature review (SLR) and meta-analysis (MA) were conducted to assess the clinical and economic burden of AMR in Japan.

Methods

Comprehensive literature searches were performed on EMBASE, MEDLINE, the Cochrane Library, and ICHUSHI between 2012 and 2022 following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. MA estimated a pooled effect between the two comparative arms (AMR vs. non-AMR). The results were reported in measures of odds ratios (ORs) for in-hospital mortality and in standardized mean differences (SMDs) for length of stay (LOS) and direct medical costs.

Results

Literature searches identified 1256 de-duplicated records, of which 56 observational studies (English, n = 35; Japanese, n = 21) were included. Of note, twenty-two studies (39.3%) compared the AMR group with non-AMR group. In the SLR, in-hospital mortality, LOS, and direct medical costs were higher in the AMR group compared to the non-AMR group. Eight studies were selected for the MA. In the AMR group, the pooled estimate showed a statistically higher in-hospital mortality [random effect (RE)—OR 2.25, 95% CI 1.34–3.79; I2 = 89%; τ2 = 0.2257, p < 0.01], LOS (RE—SMD 0.37, 95% CI  − 0.09–0.84; I2 = 99%; τ2 = 0.3600, p < 0.01), and direct medical cost (RE—SMD 0.53, 95% CI 0.43–0.62; I2 = 0.0%; τ2 = 0.0, p = 0.88) versus the non-AMR group.

Conclusion

Our study presents an overview of the clinical and economic burden of AMR in Japan. Patients with AMR infections experience significantly higher in-hospital mortality, LOS, and direct medical costs compared with patients without AMR infections.
Appendix
Available only for authorised users
Literature
1.
2.
Altarac D, Gutch M, Mueller J, Ronsheim M, Tommasi R, Perros M. Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics. Drug Discov Today. 2021;26(9):2084–9.PubMedCrossRef
3.
Pulingam T, Parumasivam T, Gazzali AM, Sulaiman AM, Chee JY, Lakshmanan M, et al. Antimicrobial resistance: prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci. 2022;170: 106103.PubMedCrossRef
4.
5.
Antimicrobial RC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef
6.
Tsuzuki S, Matsunaga N, Yahara K, Gu Y, Hayakawa K, Hirabayashi A, et al. National trend of blood-stream infection attributable deaths caused by Staphylococcus aureus and Escherichia coli in Japan. J Infect Chemother. 2020;26(4):367–71.PubMedCrossRef
7.
8.
Van Katwyk SR, Grimshaw JM, Hoffman SJ. Ten Years of inaction on antimicrobial resistance: an environmental scan of policies in Canada from 2008 to 2018. Healthc Policy. 2020;15(4):48–62.PubMedPubMedCentral
9.
Matsumoto T, Darlington O, Miller R, Gordon J, McEwan P, Ohashi T, et al. Estimating the economic and clinical value of reducing antimicrobial resistance to three gram-negative pathogens in Japan. J Health Econ Outcomes Res. 2021;8(2):64–75.PubMedPubMedCentralCrossRef
10.
11.
12.
13.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.PubMedPubMedCentralCrossRef
14.
Amir-Behghadami M, Janati A. Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387.PubMedCrossRef
15.
16.
17.
Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020;7(1):7.PubMedPubMedCentral
18.
Wells GA, Wells G, Shea B, Shea B, O'Connell D, Peterson J, et al., editors. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014.
19.
20.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–29.CrossRef
21.
McGrath S, Sohn H, Steele R, Benedetti A. Meta-analysis of the difference of medians. Biom J. 2020;62(1):69–98.PubMedCrossRef
22.
Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. 1st ed. Boca Raton: Chapman & Hall/CRC Press; 2021. p. 2021.CrossRef
23.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef
24.
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343: d4002.PubMedCrossRef
25.
26.
Suehiro T, Takahashi Y, Okushita Y, Shiraishi A, Ogawa M, Imozuka K, et al. Detection of MRSA and ESBL-producing bacteria in emergency hospitalized patients [Japanese] [臨牀指針 緊急入院患者における MRSA および ESBL 産生菌の検出状況について]. Jpn J Clin Exp Med. 2012;89(6):813–5.
27.
Kohno J, Kawamura T, Kikuchi A, Akaishi T, Takayama S, Ishii T. A Japanese traditional medicine Hochuekkito promotes negative conversion of vancomycin-resistant Enterococci. Sci Rep. 2021;11(1):11300.PubMedPubMedCentralCrossRef
28.
Hanada S, Iwata S, Kishi K, Morozumi M, Chiba N, Wajima T, et al. Host factors and biomarkers associated with poor outcomes in adults with invasive pneumococcal disease. PLoS One. 2016;11(1): e0147877.PubMedPubMedCentralCrossRef
29.
Yamagata A, Ito A, Nakanishi Y, Ishida T. Prognostic factors in nursing and healthcare-associated pneumonia. J Infect Chemother. 2020;26(6):563–9.PubMedCrossRef
30.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985–95.PubMedCrossRef
31.
Hamada Y, Magarifuchi H, Oho M, Kusaba K, Nagasawa Z, Fukuoka M, et al. Clinical features of enterococcal bacteremia due to ampicillin-susceptible and ampicillin-resistant enterococci: an eight-year retrospective comparison study. J Infect Chemother. 2015;21(7):527–30.PubMedCrossRef
32.
Hattori H, Maeda M, Nagatomo Y, Takuma T, Niki Y, Naito Y, et al. Epidemiology and risk factors for mortality in bloodstream infections: a single-center retrospective study in Japan. Am J Infect Control. 2018;46(12):e75–9.PubMedCrossRef
33.
Kainuma A, Momiyama K, Kimura T, Akiyama K, Inoue K, Naito Y, et al. An outbreak of fluoroquinolone-resistant Pseudomonas aeruginosa ST357 harboring the exoU gene. J Infect Chemother. 2018;24(8):615–22.PubMedCrossRef
34.
Yamada K, Imoto W, Yamairi K, Shibata W, Namikawa H, Yoshii N, et al. The intervention by an antimicrobial stewardship team can improve clinical and microbiological outcomes of resistant gram-negative bacteria. J Infect Chemother. 2019;25(12):1001–6.PubMedCrossRef
35.
Hanaoka N, Etoh S, Fujiyoshi N, Hirata T, Omura K. Antimicrobial therapy for multi-drug resistant Pseudomonas aeruginosa (MDRP) infection in patients with severe burns, admitted to Chiba emergency medical center [Japanese] [当医療センターでの重症熱傷患者における多剤耐性緑膿菌感染症に対しての抗菌薬療法]. Jpn J Intensive Care Med. 2013;37(4):311–8.
36.
Nagao M. A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals. Clin Microbiol Infect. 2013;19(9):852–8.PubMedCrossRef
37.
Ueda S, Okada M, Ito T, Kobayashi K, Takahashi T, Marumo S, et al. Comparative study of the effects of different dosing frequencies of cefmetazole on urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli [Japanese] [基質特異性拡張型 β-ラクタマーゼ産生大腸菌に起因する尿路感染症に対するセフメタゾールの投与回数の違いによる有効性の比較検討]. J Jpn Soc Hosp Pharm. 2022;58(2):167–72.
38.
Mitsuboshi S, Tsuruma N, Watanabe K, Takahashi S, Ito A, Nakashita M, et al. Advanced age is not a risk factor for mortality in patients with Bacteremia caused by extended-spectrum β-lactamase-producing organisms: a multicenter cohort Study. Jpn J Infect Dis. 2020;73(4):288–92.PubMedCrossRef
39.
Tetsuka N, Hirabayashi A, Matsumoto A, Oka K, Hara Y, Morioka H, et al. Molecular epidemiological analysis and risk factors for acquisition of carbapenemase-producing Enterobacter cloacae complex in a Japanese university hospital. Antimicrob Resist Infect Control. 2019;8:126.PubMedPubMedCentralCrossRef
40.
Hayakawa K, Nakano R, Hase R, Shimatani M, Kato H, Hasumi J, et al. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2020;75(3):697–708.PubMedCrossRef
41.
Imai S, Inoue N, Nagai H. Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan. BMC Infect Dis. 2022;22(1):581.PubMedPubMedCentralCrossRef
42.
Furukawa D, Asai S, Nakgohri T. Trend of methicillin - resistant Staphylococcus aureus isolation in gastroenterological surgery] [Japanese] [消化器外科におけるメチシリン耐性黄色ブドウ球菌検出の動向]. J Jpn Soc Surg Infect. 2012;9(2):143–50.
43.
Sano T. MRSA infection of department of respiratory medicine [Japanese] [本学における MRSA 感染症の現状 呼吸器内科における MRSA 感染症の現状]. J Med Soc Toho Univ. 2012;59(6):320–2.
44.
Iwabuchi H, Oguchi K. Actual status of sepsis and countermeasures [Japanese] [4. 敗血症の実態と対策]. J Jpn Soc Dial Ther. 2013;46(2):176–8.CrossRef
45.
The Japanese Society of Intensive Care Medicine CoSR. 2007 JSICM Sepsis 1st Registry: management of severe sepsis and septic shock in Japan. J Jpn Soc Intensive Care Med. 2013;20(2):329–34.CrossRef
46.
Nakatsuka Y, Morimoto C, Yasuda I, Tsuji T, Kaji Y, Yasuda T, et al. An analysis of the correlation between guidelines-concordant treatment and the treatment outcome on nursing and healthcare-associated pneumonia patients. Kansenshogaku Zasshi. 2013;87(6):739–45.PubMedCrossRef
47.
Sasaki S, Kuwana Y, Chimori A, Yoshida K. Epidemiological characterization of clinically isolated MRSA in Kinki Central Hospital, mainly for vancomycin MIC [Japanese] [近畿中央病院における MRSA 臨床分離株の疫学調査]. Med J Kinki Central Hosp. 2015;35:25–32.
48.
Kawamura I, Sekiya N, Araoka H, Nei T, Harada S, Kurai H, et al. Surveillance of Methicillin-resistant Staphylococcus aureus in 7 Japanese Hospitals, 2015. Jpn J Infect Prevent Control. 2017;32(3):135–40.CrossRef
49.
Fukushima M, Maeda A, Soga H, Tomono Y, Machida S, Oi Z, et al. Effects of AST activity on MRSA bacteremia using the automatic simultaneous multi-item genetic testing system (Verigene system) [Japanese] [自動多項目同時遺伝子関連検査システム (Verigeneシステム) を利用した MRSA 菌血症に対する AST 活動の効果]. J Jpn Soc Hosp Pharm. 2022;58(5):545–50.
50.
Mizokami F, Shibasaki M, Yoshizue Y, Noro T, Mizuno T, Furuta K. Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2013;8:1015–21.PubMedPubMedCentralCrossRef
51.
Shoji H, Urakawa T, Watanabe K, Hirano T, Katsumi K, Ohashi M, et al. Clinical features, outcomes, and survival factor in patients with vertebral osteomyelitis infected by methicillin-resistant staphylococci. J Orthop Sci. 2016;21(3):282–6.PubMedCrossRef
52.
Isobe M, Uejima E, Seki M, Yamagishi Y, Miyawaki K, Yabuno K, et al. Methicillin-resistant Staphylococcus aureus bacteremia at a university hospital in Japan. J Infect Chemother. 2012;18(6):841–7.PubMedCrossRef
53.
Kaku N, Yanagihara K, Morinaga Y, Yamada K, Harada Y, Migiyama Y, et al. Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia. J Infect Chemother. 2014;20(6):350–5.PubMedCrossRef
54.
Seki M, Takahashi H, Yamamoto N, Hamaguchi S, Ojima M, Hirose T, et al. Polymerase chain reaction-based active surveillance of MRSA in emergency department patients. Infect Drug Resist. 2015;8:113–8.PubMedPubMedCentralCrossRef
55.
Shoji H, Maeda M, Shirakura T, Takuma T, Ugajin K, Fukuchi K, et al. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2015;46(5):532–7.PubMedCrossRef
56.
Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y. The economic burden of methicillin-resistant Staphylococcus aureus in community-onset pneumonia inpatients. Am J Infect Control. 2016;44(12):1628–33.PubMedCrossRef
57.
Shime N, Saito N, Bokui M, Sakane N, Kamimura M, Shinohara T, et al. Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections. Infect Drug Resist. 2018;11:1073–81.PubMedPubMedCentralCrossRef
58.
Uematsu H, Yamashita K, Mizuno S, Kunisawa S, Shibayama K, Imanaka Y. Effect of methicillin-resistant Staphylococcus aureus in Japan. Am J Infect Control. 2018;46(10):1142–7.PubMedCrossRef
59.
Yuasa A, Murata T, Imai K, Yamamoto Y, Fujimoto Y. Treatment procedures and associated medical costs of methicillin-resistant Staphylococcus aureus infection in Japan: a retrospective analysis using a database of Japanese employment-based health insurance. SAGE Open Med. 2019;7:2050312119871181.PubMedPubMedCentralCrossRef
60.
Miyazaki T, Yanagihara K, Kakeya H, Izumikawa K, Mukae H, Shindo Y, et al. Daily practice and prognostic factors for pneumonia caused by methicillin-resistant Staphylococcus aureus in Japan: a multicenter prospective observational cohort study. J Infect Chemother. 2020;26(2):242–51.PubMedCrossRef
61.
Umemura Y, Ogura H, Takuma K, Fujishima S, Abe T, Kushimoto S, et al. Current spectrum of causative pathogens in sepsis: a prospective nationwide cohort study in Japan. Int J Infect Dis. 2021;103:343–51.PubMedCrossRef
62.
Tsuzuki S, Yu J, Matsunaga N, Ohmagari N. Length of stay, hospitalisation costs and in-hospital mortality of methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia in Japan. Public Health. 2021;198:292–6.PubMedCrossRef
63.
Sakamoto Y, Yamauchi Y, Jo T, Michihata N, Hasegawa W, Takeshima H, et al. In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study. BMC Pulm Med. 2021;21(1):345.PubMedPubMedCentralCrossRef
64.
Shimizu M, Mihara T, Ohara J, Inoue K, Kinoshita M, Sawa T. Relationship between mortality and molecular epidemiology of methicillin-resistant Staphylococcus aureus bacteremia. PLoS One. 2022;17(7): e0271115.PubMedPubMedCentralCrossRef
65.
Uematsu H, Yamashita K, Kunisawa S, Fushimi K, Imanaka Y. Estimating the disease burden of methicillin-resistant Staphylococcus aureus in Japan: retrospective database study of Japanese hospitals. PLoS One. 2017;12(6): e0179767.PubMedPubMedCentralCrossRef
66.
Aoyagi T, Kaito C, Sekimizu K, Omae Y, Saito Y, Mao H, et al. Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan. Clin Microbiol Infect. 2014;20(9):912–9.PubMedCrossRef
67.
Asai N, Sakanashi D, Suematsu H, Kato H, Hagihara M, Nishiyama N, et al. The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: case control study in a single institute in Japan. J Infect Chemother. 2018;24(7):505–9.PubMedCrossRef
68.
Fukuda H, Sato D, Iwamoto T, Yamada K, Matsushita K. Healthcare resources attributable to methicillin-resistant Staphylococcus aureus orthopedic surgical site infections. Sci Rep. 2020;10(1):17059.PubMedPubMedCentralCrossRef
69.
Kashimura N, Kusachi S, Konishi T, Shimizu J, Kusunoki M, Oka M, et al. Impact of surgical site infection after colorectal surgery on hospital stay and medical expenditure in Japan. Surg Today. 2012;42(7):639–45.PubMedCrossRef
70.
Naylor NR, Yamashita K, Iwami M, Kunisawa S, Mizuno S, Castro-Sanchez E, et al. Code-sharing in cost-of-illness calculations: an application to antibiotic-resistant bloodstream infections. Front Public Health. 2020;8: 562427.PubMedPubMedCentralCrossRef
71.
Obara H, Saitou J, Fukuda H. Increased burden on medical resources of penicillin-resistant streptococcus pneumoniae infections: estimates using JANIS data. Jpn J Infect Prevent Control. 2015;30(3):165–73.CrossRef
72.
Saito S, Hayakawa K, Tsuzuki S, Ishikane M, Nagashima M, Mezaki K, et al. A matched case-case-control study of the impact of clinical outcomes and risk factors of patients with IMP-type carbapenemase-producing carbapenem-resistant enterobacteriaceae in Japan. Antimicrob Agents Chemother. 2021;65(3). https://​doi.​org/​10.​1128/​aac.​01483-20.
73.
Uryu K, Nishiura S, Yamamoto T, Umakosi T, Nisida M, Suzuki M, et al. Changes in medical treatment fees for pneumococcal pneumonia in our hospital before and after the introduction of DPC. J Jpn Soc Clin Pathway. 2012;14(2):113–21.
74.
Maeda M, Oto Y, Murayama J, Minemura A, Baba T, Yoshida H, et al. A study of risk factors for antibiotic selective pressure in Carbapenem-treated patients [Japanese] [カルバペネム系薬投与患者における耐性菌選択リスク因子の検討]. J Showa Univ Soc. 2014;74(1):67–72.
75.
Osumi T, Tanaka D, Eguchi T, Imai T, Shimizu H, Sakai M, et al. retrospective study of initiation of empirical therapies out of the antibacterial spectrum for urinary tract infections presumed to be caused by extended spectrum β-lactamases producing bacteria [Japanese] [ESBL 産生菌が原因と推定される尿路感染症にスペクトラムが外れた経験的治療を開始したことが及ぼす影響の後方視的検討]. J Jpn Soc Hosp Pharm. 2021;57(11):1215–20.
76.
Kobayashi H, Moriyama Y, Kurosu H. Report methicillin-resistant Staphylococcus aureus hospital infection surveillance for the fiscal year 2011 [Japanese] [報告 2011年度の Methicillin-resistant Staphylococcus aureus 病院感染症サーベイランス]. Jpn J Infect Prevent Control. 2013;28(3):178–9.CrossRef
77.
Ogasahara Y, Nagasaki N, Ohno K, Harino T, Yoshida T, Maruko M. Factors causing P. aeruginosa resistance in patients treated with meropenem [Japanese] [Meropenem 投与患者における緑膿菌耐性化因子の検討]. Jpn J Infect Prevent Control. 2012;27(6):419–24.CrossRef
78.
Kosuge Y, Nagashima G, Enomoto K, Kato A, Noda M, Morishima H, et al. Clinical characteristics of multidrug-resistant bacteria infection with stroke [Japanese] [脳卒中患者における多剤耐性菌感染症の臨床検討]. Neurosurg Emerg. 2013;18(2):173–6.
79.
Fukatsu M, Umemura T, Mizuno T, Ohguchi H, Iwatsu S, Matsumoto S, et al. Positive impacts of antimicrobial stewardship on intial eradication success and drug costs of treatment for clarithromycin-reisistant helicobacter pyloriInfections [Japanese] [薬剤師によるクラリスロマイシン耐性 Helicobacter pylori 感染に対する抗菌薬適正使用支援が初回除菌率と薬剤費に与える影響]. Jpn J Pharm Health Care Sci. 2021;47(11):609–15.CrossRef
80.
Suzuki T, Tsuchiya M, Niwa T, Watanabe T, Ohta H, Fukako A, et al. Cost effectiveness of controlling healthcare-associated spread of methicillin-resistant Staphylococcus aureus [Japanese] [当院における MRSA 感染制御活動の経済的評価に関する検討]. Jpn J Infect Prevent Control. 2015;30(2):91–6.CrossRef
81.
Goto Y, Hayashi M, Akasaki J, Ito M, Yamamoto K, Sawa A, et al. Study of risk factors for carriage of vancomycin-resistant enterococcus [Japanese] [バンコマイシン耐性腸球菌の保菌におけるリスク因子の検討]. J Jpn Soc Hospital Pharm. 2014;4:499–502.
82.
Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58.PubMedPubMedCentralCrossRef
83.
84.
85.
Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol. 2020;41(1):1–18.PubMedCrossRef
86.
87.
Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166–74.PubMedCrossRef
88.
Thampi N, Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, et al. Multicenter study of health care cost of patients admitted to hospital with Staphylococcus aureus bacteremia: impact of length of stay and intensity of care. Am J Infect Control. 2015;43(7):739–44.PubMedCrossRef
89.
90.
Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, et al. The economic burden of antibiotic resistance: a systematic review and meta-analysis. PLoS One. 2023;18(5): e0285170.PubMedPubMedCentralCrossRef
91.
Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–9.PubMedCrossRef
92.
93.
MacKinnon MC, Sargeant JM, Pearl DL, Reid-Smith RJ, Carson CA, Parmley EJ, et al. Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):200.PubMedPubMedCentralCrossRef
94.
Wozniak TM, Barnsbee L, Lee XJ, Pacella RE. Using the best available data to estimate the cost of antimicrobial resistance: a systematic review. Antimicrob Resist Infect Control. 2019;8:26.PubMedPubMedCentralCrossRef
Metadata
Title
Burden of Antimicrobial Resistance in Japan: A Systematic Literature Review and Meta-Analysis
Authors
Tetsuya Matsumoto
Akira Yuasa
Hiroyuki Matsuda
Dilinuer Ainiwaer
Naohiro Yonemoto
Publication date
25-04-2024
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-024-00960-z
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits